liver
Changes in levels of endocannabinoidome mediators in mice with cancer cachexia: links with steatosis and gut microbial dysbiosis.
BACKGROUND
Cachexia is a debilitating syndrome associated with involuntary weight loss, often occurring in cancer patients. In both humans and animal models, alterations in endocannabinoid (eCB) signaling occur in association with both metabolic disorders and several types of tumors. The wider...
Screening for Malnutrition, Sarcopenia, and Physical Frailty Beyond One Year after Liver Transplantation.
BACKGROUND/AIMS
Malnutrition, sarcopenia, and frailty negatively impact quality of life and increase mortality following liver transplantation (LT). However, long-term follow-up data remain limited. This study aimed primarily to assess the malnutrition risk at 1-, 2-, and 3-years post-LT. Secondary objectives included...
Primary-Stage Colon Cancer Impairs Muscle Energy Metabolism by Suppressing Mitochondrial Complex I Activity.
BACKGROUND
Colon cancer (CC), the third most common cancer worldwide, is accompanied by cachexia in 30% of patients. Its associated muscle loss directly impairs therapeutic response and survival. Early intervention is crucial, yet the underlying mechanisms of early-stage muscle dysfunction remain...
Reframing cancer cachexia: the vagal brain-liver axis as a novel neuro-metabolic target.
Sarcopenia and MASLD: novel insights and the future.
Metabolic dysfunction-associated steatotic liver disease (MASLD; previously known as non-alcoholic fatty liver disease) is the leading cause of chronic liver disease worldwide and is closely linked to the obesity epidemic. MASLD often coexists with sarcopenia, an age-related loss of muscle...
Effect of Skeletal Muscle Mass and Its Associated Mediators on the Development of Steatotic Liver Disease: A Cohort Study in China.
BACKGROUND
Understanding the relationship between relative skeletal muscle mass and newly proposed steatotic liver disease (SLD) is crucial, but research gaps still exist. Based on a cohort study, we investigated the impact of relative skeletal muscle mass on incident SLD and...
Overt hepatic encephalopathy after elective and preemptive TIPS: Risk factors and prognosis.
BACKGROUND & AIMS
Overt hepatic encephalopathy (OHE) develops in 30-50% of patients after transjugular intrahepatic portosystemic shunt (TIPS) placement, depending on patient characteristics and TIPS indication. Data on OHE after preemptive TIPS (pTIPS) are limited. We aimed to assess the prevalence...
Sarcopenia and gender disparities in liver transplant waiting lists: evaluating predictive scores and delisting risks.
BACKGROUND
The model for end-stage liver disease (MELD) and model for end-stage liver disease-sodium (MELD-Na) scores are the most widely used for prioritizing patients on the liver transplant (LT) waiting list. However, the quality and accuracy of these scores are questionable....
Association of Hormonal Status With Sarcopenia, Frailty and Outcome in Patients With Decompensated Cirrhosis.
BACKGROUND AND AIMS
Sarcopenia and frailty have been associated with hormonal dysregulation in non-cirrhotic populations. The aim of the study was to evaluate hypothalamic-pituitary-adrenal and gonadal (HPA-HPG) axes as well as growth hormone/insulin-like growth factor-1 (GH/IGF-1) levels in patients with cirrhosis...
Management of Children Awaiting Liver Transplantation: Sarcopenia, Cholestasis and Beyond.
Sarcopenia has been increasingly recognized as a risk factor for worse outcomes in liver transplantation; however, the data remain limited on pediatric-specific outcomes. These gaps in knowledge are in part due to the lack of a standardized definition, challenges inherent...
Silencing Myostatin Using In Vivo Self-Assembled siRNA Protects Against Cancer- and Dexamethasone-Induced Muscle Atrophy.
Maintaining skeletal muscle mass is crucial for health, as muscle atrophy caused by drugs, cancer, or aging poses serious risks. However, there are few effective pharmacological interventions targeting muscle atrophy, highlighting the need for new therapeutic strategies. In this study,...
Type II fibre atrophy and nuclear disruption in decompensated cirrhosis.
Loss of skeletal muscle mass is a common complication in cirrhosis that is associated with higher morbidity and mortality. Since the specific pathophysiology of cirrhosis-related muscle loss is unclear, we performed histological evaluation of muscle tissue from patients with cirrhosis...
Vagal blockade of the brain-liver axis deters cancer-associated cachexia.
Cancer-associated cachexia (CAC) is a multifactorial and currently incurable syndrome responsible for nearly one-third of cancer-related deaths. It contributes to therapy resistance and increases mortality among affected patients. In this study, we show that cancer-induced systemic inflammation alters vagal tone...
Cancer therapy and cachexia.
A central challenge in cancer therapy is the effective delivery of anticancer treatments while minimizing adverse effects on patient health. The potential dual impact of therapy is clearly illustrated in cancer-associated cachexia, a multifactorial syndrome characterized by involuntary weight loss,...
Functional liver genomics identifies hepatokines promoting wasting in cancer cachexia.
In cancer cachexia, the presence of a tumor triggers systemic metabolic disruption that leads to involuntary body weight loss and accelerated mortality in affected patients. Here, we conducted transcriptomic and epigenomic profiling of the liver in various weight-stable cancer and...
